Sequence Bio

Drug target discovery powered by the founder effect

First Investment: 2016

In Newfoundland and Labrador, the founder effect means there’s less genetic variability, making it easier to use population multi-omics to find true signals of disease — gene variants with low frequency but high impact. Sequence Bio works with leading pharma and biotech companies to discover better drug targets, build custom cohorts of volunteers for clinical trials, and shorten R&D timelines.

Explore Companies

Syntax Bio

Programming stem cells to differentiate into desired cell types, faster

Fable Therapeutics

Using state-of-the-art machine learning models to create custom-build protein drugs

Nilo Therapeutics

Mapping the brain-body axis to achieve proper immune balance

Avicenna Biosciences

Using AI to speed through the last mile of drug discovery